CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
BetaGlue is developing BAT-90, a novel radiotherapy platform that delivers targeted treatment directly to tumors. This approach aims to minimize side effects and improve outcomes for patients with difficult-to-treat solid tumors, such as liver and pancreatic cancers.
BetaGlue is developing an innovative ""radiotherapy from within"", personalized and cost-effective anti-tumoural platform technology called BAT-90. BAT-90 maximises the therapeutic index of loco-regional treatment by eliminating off-target radiation dose in a simple and easy to use product.
The product aims to provide a radiotherapeutic treatment option for a range of solid tumour types including: unresectable hepatocellular carcinoma (HCC) and locally advanced and borderline resectable pancreat…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
